HilleVax Q3 2023 Earnings Report
Key Takeaways
HilleVax reported a net loss of $31.8 million for the third quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $324.4 million as of September 30, 2023. Research and development expenses for the third quarter 2023 were $27.3 million.
Closed an underwritten public offering of 9,200,000 shares of its common stock at a price of $12.50 per share for gross proceeds of $115.0 million in Q3 2023.
Initiated three clinical trials supporting the advancement of HIL-214 in Q3 2023; NOR-109, NOR-206, and NOR-215, and completed enrollment of subjects in all three clinical trials as of October 2023.
Announced completion of enrollment of the NEST-IN1 Phase 2b clinical trial with over 3,000 subjects enrolled in six countries in Q2 2023.
Topline safety and clinical efficacy data from NEST-IN1 is expected in mid-2024.
HilleVax
HilleVax
Forward Guidance
HilleVax is expecting topline safety and clinical efficacy data from NEST-IN1 in mid-2024.